Intravesical instillation of thiotepa is a popular treatment for localized bladder carcinoma. The drug can enter the systemic circulation, and such absorption may be enhanced by extensive tumour infiltration or by a recent tumour resection. A case is reported of early onset life-threatening pancytopenia following an unusually low dose of the drug in a patient who had undergone a recent tumour resection.
Introduction
The efficacy of intravesical instillation therapy with thiotepa (N-N'-N'-thiethylene-thiophosphoramide), a poly-functioning alkylating agent, against bladder carcinoma was first reported by Jones and Swinney (1961) . Subsequently, many clinical evaluations of this therapy have been performed regarding the direct destruction of and prophylaxis against bladder carcinoma (Abbassian and Wallace, 1966; Wescott, 1966; Drew and Marchall, 1968;  Veenema, Dean and Uson, 1969; Pavone-Macaluso, Caramia and Rizzo, 1971; Tomiyama, 1972) . At present, thiotepa remains a popular agent for the treatment of localized bladder carcinoma. Reduction in the extension of tumour or even complete eradication may be obtained in about one-third of the patients if they are treated with instillations of thiotepa (Prout, 1974) . The chief disadvantage of this therapy is the absorption of thiotepa into the circulating blood through the bladder wall. As with other alkylating agents, dose-related myelosuppression is a wellknown toxic effect, regardless of the route of administration. We report here a case of early onset lifethreatening pancytopenia following an unusually low dose of the drug. 
